Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

Harvard Bioscience (NASDAQ:HBIO - Get Rating) was downgraded by equities research analysts at TheStreet from a "c" rating to a "d+" rating in a research note issued to investors on Monday, TheStreetRatingsTable reports.

Several other equities research analysts also recently issued reports on the stock. StockNews.com started coverage on shares of Harvard Bioscience in a research report on Thursday, March 31st. They set a "hold" rating for the company. Zacks Investment Research upgraded shares of Harvard Bioscience from a "hold" rating to a "buy" rating and set a $4.25 price target for the company in a research note on Tuesday, May 17th.

Shares of HBIO stock opened at $3.79 on Monday. Harvard Bioscience has a 1 year low of $3.36 and a 1 year high of $8.75. The firm's 50 day moving average is $5.30 and its 200-day moving average is $6.03. The firm has a market capitalization of $156.30 million, a price-to-earnings ratio of -23.69 and a beta of 1.84. The company has a current ratio of 2.18, a quick ratio of 1.13 and a debt-to-equity ratio of 0.61.

Whether you're looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today's futures markets!

Harvard Bioscience (NASDAQ:HBIO - Get Rating) last announced its earnings results on Wednesday, May 4th. The medical instruments supplier reported $0.04 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.05 by ($0.01). Harvard Bioscience had a positive return on equity of 9.06% and a negative net margin of 5.38%. During the same quarter last year, the business earned $0.03 EPS. On average, equities research analysts forecast that Harvard Bioscience will post 0.26 earnings per share for the current fiscal year.

In other Harvard Bioscience news, CEO James W. Green bought 30,000 shares of the business's stock in a transaction that occurred on Friday, May 6th. The shares were acquired at an average cost of $3.78 per share, for a total transaction of $113,400.00. Following the transaction, the chief executive officer now directly owns 2,309,955 shares in the company, valued at $8,731,629.90. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO James W. Green bought 10,000 shares of the business's stock in a transaction that occurred on Monday, May 9th. The shares were acquired at an average price of $3.40 per share, for a total transaction of $34,000.00. Following the completion of the transaction, the chief executive officer now owns 2,319,955 shares in the company, valued at $7,887,847. The disclosure for this purchase can be found here. Company insiders own 6.20% of the company's stock.

A number of institutional investors have recently added to or reduced their stakes in HBIO. B. Riley Asset Management LLC increased its stake in shares of Harvard Bioscience by 48.2% in the 1st quarter. B. Riley Asset Management LLC now owns 898,436 shares of the medical instruments supplier's stock valued at $5,579,000 after acquiring an additional 292,042 shares in the last quarter. State Street Corp increased its stake in shares of Harvard Bioscience by 5.6% in the 1st quarter. State Street Corp now owns 742,929 shares of the medical instruments supplier's stock valued at $4,614,000 after acquiring an additional 39,174 shares in the last quarter. Engineers Gate Manager LP increased its stake in shares of Harvard Bioscience by 44.3% in the 1st quarter. Engineers Gate Manager LP now owns 59,738 shares of the medical instruments supplier's stock valued at $371,000 after acquiring an additional 18,347 shares in the last quarter. Meros Investment Management LP increased its stake in Harvard Bioscience by 21.5% during the 1st quarter. Meros Investment Management LP now owns 525,586 shares of the medical instruments supplier's stock valued at $3,263,000 after purchasing an additional 93,141 shares in the last quarter. Finally, Renaissance Technologies LLC increased its stake in Harvard Bioscience by 4.7% during the 1st quarter. Renaissance Technologies LLC now owns 948,445 shares of the medical instruments supplier's stock valued at $5,890,000 after purchasing an additional 42,500 shares in the last quarter. Hedge funds and other institutional investors own 72.75% of the company's stock.

About Harvard Bioscience (Get Rating)

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments.

See AlsoGet a free copy of the StockNews.com research report on Harvard Bioscience (HBIO)Investors Can Get 5%-Plus Dividend Yields on These 3 BuysIt’s Time to Buy into Planet Fitness StockIndie Semiconductor Stock is Putting in a BottomTwo Retailers, One To Buy And One To Avoid 3 Defensive Consumer Stocks Worth Shopping For

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Before you consider Harvard Bioscience, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harvard Bioscience wasn't on the list.

While Harvard Bioscience currently has a "N/A" rating among analysts, top-rated analysts believe these five stocks are better buys.

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:

Each market day you'll get a one-minute market summary to help you invest wisely.

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved. 326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257 MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.